China Biologic Products Holdings
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of China Biologic Products Holdings generated cash of $258,477,921, which is more than the previous year. Cash used in financing activities reached the amount of -$12,065,816 last year. Net change in cash is therefore $513,581,036.
Cash Flow
| 2011 | 38.46M | -7.12M | -10.07M |
|---|---|---|---|
| 2012 | 71.09M | -26.75M | -5.10M |
| 2013 | 74.30M | -25.56M | -38.52M |
| 2014 | 93.51M | -13.40M | -142.82M |
| 2015 | 109.39M | -89.75M | 51.57M |
| 2016 | 123.25M | -52.52M | -22.08M |
| 2017 | 102.18M | -60.89M | -18.32M |
| 2018 | 103.94M | -558.94M | 571.30M |
| 2019 | 229.34M | -180.14M | -229.46M |
| 2020 | 258.47M | 263.00M | -12.06M |
CBPO Cash Flow Statement (2011 – 2020)
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 161.75M | 338.88M | 219.33M | 183.76M | 144.93M | 80.82M | 144.13M | 129.60M | 89.41M | 64.94M |
Operating activities | ||||||||||
Net income | 152.28M | 138.80M | 128.05M | 67.94M | 104.77M | 89.04M | 70.91M | 54.60M | 45.22M | 18.18M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 27.19M | 26.24M | 23.22M | 12.90M | 12.73M | 9.03M | 7.74M | 7.46M | 8.88M | 7.64M |
Stock-based compensation expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.05M | 4.54M | 4.89M |
| Deferred income tax benefit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.05M | 4.54M | 4.89M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -5.50M | 22.13M | -53.87M | -39.91M | -10.97M | -7.14M | -2.19M | -5.66M | 5.68M | -6.12M |
Inventories | 5.46M | -14.84M | -42.59M | -42.07M | -40.07M | -32.09M | -13.41M | -10.43M | -3.75M | -17.07M |
Accounts payable | -2.05M | -1.29M | 8.14M | 977.15K | 2.96M | 5.34M | 405.07K | 1.62M | -2.18M | 431.83K |
Cash generated by operating activities | 258.47M | 229.34M | 103.94M | 102.18M | 123.25M | 109.39M | 93.51M | 74.30M | 71.09M | 38.46M |
Investing activities | ||||||||||
Purchases Of Investments | -2.66B | -2.60B | -2.73B | -22.66M | 0 | 0 | 0 | -6.60M | 0 | 0 |
Investments In Property Plant And Equipment | -21.03M | -24.43M | -36.71M | -38.29M | -51.00M | -52.29M | -21.87M | -21.81M | -27.94M | -8.39M |
Acquisitions Net | 2.12M | 0 | 98M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 263.00M | -180.14M | -558.94M | -60.89M | -52.52M | -89.75M | -13.40M | -25.56M | -26.75M | -7.12M |
Financing activities | ||||||||||
Common Stock Issued | 0 | 9.03M | 590.26M | 0 | 0 | 80.58M | 33.21M | 0 | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | -110.04M | -10M | 0 | 0 | 0 | -70M | -29.59M | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | -56.53M | -8.01M | -14.28M | -10.84M |
Cash used in financing activities | -12.06M | -229.46M | 571.30M | -18.32M | -22.08M | 51.57M | -142.82M | -38.52M | -5.10M | -10.07M |
Net Change In Cash | 513.58M | -177.13M | 119.54M | 35.57M | 38.82M | 64.11M | -63.31M | 14.52M | 40.19M | 24.47M |
Cash at end of period | 675.33M | 161.75M | 338.88M | 219.33M | 183.76M | 144.93M | 80.82M | 144.13M | 129.60M | 89.41M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |